Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 7/20 | 0.41 |
| ▸ | BRAF | P15056 | 5/20 | 0.33 |
| ▸ | IKBKB | O14920 | 2/20 | 0.32 |
| ▸ | CHUK | O15111 | 2/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19876272 | 0.78 | BTK (0.56) | BRD4BTK | |
| SCHEMBL19876236 | 0.74 | BTK (0.55) | BTK | |
| SCHEMBL19876216 | 0.71 | BTK (0.57) | BRD4BTKBRAF | |
| Hydrochloric Acid SCHEMBL19876241 | 0.70 | BTK (0.56) | BRD4BTKBRAF | |
| SCHEMBL1503032 | 0.68 | BRD4 (0.48) | BRD4BTKBRAF | |
| SCHEMBL19876171 | 0.68 | BTK (0.47) | BRD4BTKIKBKBCHUKPRMT5 | |
| SCHEMBL17365232 | 0.65 | BRD4 (0.46) | BRD4BTKBRAF | |
| SCHEMBL31734939 | 0.65 | LRRK2 (0.38) | ROCK1 | |
| SCHEMBL26953079 | 0.65 | LRRK2 (0.38) | ROCK1 | |
| SCHEMBL31734963 | 0.63 | LRRK2 (0.54) | ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3500569-B1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2022-05-18 | — | — | EP | disclosed |
| CN-109641892-B | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof | 默克专利有限公司 | 2021-07-02 | — | — | CN | disclosed |
| EP-3500569-A1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2019-06-26 | — | — | EP | disclosed |
| US-10266528-B2 | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-23 | — | — | US | disclosed |
| WO-2018035080-A1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-02-22 | — | — | WO | disclosed |
| US-20180051024-A1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266528-B2 | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof | BTK, SYK, LCK | BRD4 85/4885BTK 1/4885BRAF 224/4885 |
| US-20180051024-A1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | BTK, SYK, LCK | BRD4 85/4885BTK 1/4885BRAF 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.